Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

High-Throughput Flow Cytometry in Drug Discovery

By SLAS (Society for Laboratory Automation and Screening) | July 24, 2018

High-throughput flow cytometry in drug discovery. Credit: Alexandre Chigaev, University of New Mexico

A new special issue of SLAS Discovery reflects examples of the recent groundswell of creative new applications for high-throughput flow cytometry (HTFC) in drug discovery.

Led by guest editors Mei Ding, Ph.D. (AstraZeneca) and Bruce S. Edwards, Ph.D. (University of New Mexico), this special issue presents a range of research papers, application notes and technical notes that reflect recent advances in HTFC methods design, provide new expert insight and perspectives, and highlight areas for improvement to broaden the range of HTFC applications in drug discovery.

Examples include descriptions of different software and data analysis workflows; the relative merits of different platforms for assessing biological responses of interest; novel HTFC applications for the development of biologic drugs and novel antibodies; target-agnostic or mechanism-informed phenotypic drug discovery; use of HTFC for single cell analysis; engineering autologous patient T cells to express chimeric antigen receptors (CAR-T) for use in adoptive cellular therapy of malignancies; and more.

Flow cytometry has proven to be a powerful technology, enabling multi-parametric analysis of single cells or particles, and widely used in a broad range of clinical and basic research and applications, including quantification of cell surface and intracellular proteins, DNA analysis, cell proliferation, cell viability, cellular granularity, and cell size. HTFC was made possible by the introduction of novel sample handling and analysis technologies.

SOURCE: SLAS (Society for Laboratory Automation and Screening)


Filed Under: Drug Discovery

 

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50